Amplia Therapeutics Ltd (ASX: ATX) Share Price and News

Price

$0.06

Movement

0.003 (+5.26%)

as at 12 Jun - Closed (20 mins delayed)

52 Week Range

$0.049 - $0.1765

 
1 Year Return

-16.14%

Amplia Therapeutics Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $23.28 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 387.95 million
Earnings per share -0.021
Dividend per share N/A
Year To Date Return -35.96%
Earnings Yield N/A
Franking -
Share Price

$0.06

Day Change

0.003 (+5.26%)

52 Week Range

$0.049 - $0.1765

Yesterday's Close

$0.057

Today's Open

$0.057

Days Range

$0.057 - $0.06

Volume

224,063

Avg. Volume (1 month)

4,413,396

Turnover

$13,277

as at 12 Jun - Closed

  • Amplia Therapeutics Ltd (ASX: ATX)
    Latest News

    Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
    Healthcare Shares

    2 ASX biotech shares rocketing more than 40% on big news

    These two ASX healthcare companies have exciting news for investors today.

    Read more »

    A medical researcher in a white coat holds laboratory equipment and smiles.
    Share Market News

    Why the Amplia (ASX:ATX) share price is rocketing 41% higher today

    The Australian pharmaceutical company sees its share price jump after good news on a drug trial.

    Read more »

    woman in lab coat conducting testing representing biotech
    Share Market News

    Here's why the Amplia (ASX:ATX) share price is up 9% today

    The Amplia Therapeutics Ltd (ASX: ATX) share price is running 9% higher today following progress on its AM945 inhibitor. Here's…

    Read more »

    Share Market News

    Amplia Therapeutics share price up 16% in 2 days as former Macquarie CEO takes substantial stake

    The Amplia Therapetics Ltd (ASX: ATX) share price has risen16% since Tuesday following an announcement that a former Macquarie CEO…

    Read more »

    a woman
    Share Market News

    US congressman resigns over ASX insider trading penny stock scandal

    Can you make money in penny stocks?

    Read more »

    a woman
    Share Market News

    ASX Watergate Arrest: The alleged insider trading at Innate Immunotherapeutics Ltd (ASX:IIL)

    A US Congressman and former director of Innate Immunotherapeutics Ltd (ASX:IIL) has been arrested for conspiracy to commit securities fraud.

    Read more »

    a woman
    Investing

    Cann Group Ltd is one of 64 new shares added to the All Ordinaries this quarter

    Cann Group Ltd (ASX:CAN) shares are one of 64 new additions to the All Ordinaries (Index:^AXAO) (ASX:XAO) this month. Here's…

    Read more »

    a woman
    Investing

    Were these the 3 worst shares on the ASX in 2017?

    The iSentia Group Ltd (ASX:ISD) share price was one of three that destroyed the wealth of unlucky shareholders in 2017…

    Read more »

    a woman
    Investing

    These are the 5 biggest losers on the All Ordinaries in the last 12 months

    The Quintis Ltd (ASX:QIN) share price is amongst the five biggest losers on the All Ordinaries (Index:^AXAO) (ASX:XAO) over the…

    Read more »

    a woman
    Investing

    One crucial thing to consider before investing in risky biotech shares

    Consider this before owning shares in companies like Resapp Health Ltd (ASX:RAP) and Innate Immunotherapeutics Ltd (ASX:IIL).

    Read more »

    a woman
    Investing

    The 3 biggest investing mistakes you can make

    Buying Commonwealth Bank of Australia (ASX:CBA) and Wesfarmers Ltd (ASX:WES) shares may sound boring, but it’s better than some alternatives.

    Read more »

    a woman
    Investing

    Here's how to get rich quick (and stay poor forever)

    Buying speculative stocks like Innate Immunotherapeutics Ltd (ASX:IIL) and Resapp Health Ltd (ASX:RAP) is not a reliable way to grow…

    Read more »

    ATX ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    30th May 2025 2025-05-30T15:14:30 Appendix 4G - Key to Corporate Governance DisclosuresYesNo3:14pm14303k
    30th May 2025 2025-05-30T15:14:21 2025 Corporate Governance StatementYesNo3:14pm16358k
    30th May 2025 2025-05-30T15:13:25 Preliminary Final Report and Annual Report YE 31 March 2025YesNo3:13pm7120M
    16th May 2025 2025-05-16T17:05:25 Change in substantial holdingYesNo5:05pm5194k
    15th May 2025 2025-05-15T08:21:39 ACCENT Trial Achieves Superiority over Chemotherapy AloneYesNo8:21am2185k
    12th May 2025 2025-05-12T08:20:14 Amplia Appoints Dr Jason Lickliter as Chief Medical OfficerYesNo8:20am2175k
    30th Apr 2025 2025-04-30T08:28:58 Quarterly Activities/Appendix 4C Cash Flow ReportYesNo8:28am7316k
    28th Apr 2025 2025-04-28T10:24:55 ACCENT Data Update Presented at International ConferenceYesNo10:24am42M
    9th Apr 2025 2025-04-09T08:20:17 US Clinical Trial Activities for Narmafotinib Now UnderwayYesNo8:20am3180k
    27th Mar 2025 2025-03-27T08:15:40 Encouraging Updated Data from Pancreatic Cancer TrialYesNo8:15am2177k

    About Amplia Therapeutics Ltd

    Amplia Therapeutics Ltd is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. Its molecule, AMP945 is a pure-play inhibitor, while the second molecule, AMP886, is a multi-action molecule that hits two other important cancer pathways: VEGFR3 and FLT3.

    ATX Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    11 Jun 2025 $0.06 $0.00 0.00% 287,000 $0.06 $0.06 $0.06
    10 Jun 2025 $0.06 $-0.01 -15.15% 2,617,501 $0.07 $0.07 $0.06
    06 Jun 2025 $0.07 $0.00 0.00% 2,020,110 $0.06 $0.07 $0.06
    05 Jun 2025 $0.06 $0.01 20.00% 8,746,743 $0.05 $0.06 $0.05
    04 Jun 2025 $0.05 $0.00 0.00% 801,194 $0.05 $0.05 $0.05
    03 Jun 2025 $0.05 $0.00 0.00% 302,069 $0.05 $0.05 $0.05
    02 Jun 2025 $0.05 $0.00 0.00% 609,155 $0.05 $0.05 $0.05
    30 May 2025 $0.05 $0.00 0.00% 404,604 $0.05 $0.05 $0.05
    29 May 2025 $0.05 $0.00 0.00% 1,481,435 $0.05 $0.05 $0.05
    28 May 2025 $0.05 $0.00 0.00% 1,019,262 $0.05 $0.05 $0.05
    27 May 2025 $0.05 $0.00 0.00% 1,834,613 $0.05 $0.05 $0.05
    26 May 2025 $0.05 $0.00 0.00% 249,662 $0.05 $0.05 $0.05
    23 May 2025 $0.05 $0.00 0.00% 1,975,453 $0.05 $0.05 $0.05
    22 May 2025 $0.05 $0.00 0.00% 293,415 $0.05 $0.05 $0.05
    21 May 2025 $0.05 $0.00 0.00% 826,457 $0.05 $0.05 $0.05
    20 May 2025 $0.05 $0.00 0.00% 2,567,590 $0.05 $0.05 $0.05
    19 May 2025 $0.05 $-0.01 -15.38% 8,869,769 $0.06 $0.06 $0.05
    16 May 2025 $0.07 $-0.01 -14.29% 5,437,807 $0.07 $0.07 $0.06
    15 May 2025 $0.07 $0.02 36.36% 56,028,459 $0.07 $0.10 $0.07
    14 May 2025 $0.06 $0.00 0.00% 66,427 $0.05 $0.06 $0.05
    13 May 2025 $0.05 $0.00 0.00% 591,958 $0.06 $0.06 $0.05

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    20 Dec 2024 Robert Peach Issued 815,218 $67,663
    As advised by the company. Participation in Capital Raise
    20 Dec 2024 Robert Peach Issued 1,086,957 $125,000
    As advised by the company. Participation in Capital Raise
    20 Dec 2024 Jane Bell Issued 521,739 $43,304
    As advised by the company. Participation in Capital Raise
    20 Dec 2024 Jane Bell Issued 695,652 $79,999
    As advised by the company. Participation in Capital Raise
    20 Dec 2024 Warwick Tong Transfer 661,107 $54,871
    Off-market transfer. Assuming off market transfer of shares
    20 Dec 2024 Warwick Tong Transfer 661,107 $54,871
    Off-market transfer. Assuming off market transfer of shares
    20 Dec 2024 Warwick Tong Issued 521,739 $43,304
    As advised by the company. Participation in Capital Raise
    20 Dec 2024 Warwick Tong Issued 695,652 $79,999
    As advised by the company. Participation in Capital Raise
    20 Dec 2024 Christopher Burns Issued 347,826 $39,999
    As advised by the company. Participation in Capital Raise
    20 Dec 2024 Christopher Burns Issued 260,869 $21,652
    As advised by the company. Participation in Capital Raise
    26 Aug 2024 Christopher Burns Issued 586,321 $36,351
    Employee Share Ownership Plan.
    19 Jun 2024 Robert Peach Buy 827,268 $45,499
    Off-market trade.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Andrew John Cooke Company Secretary Oct 2013
    Mr Cooke has experience in law, corporate finance, governance and compliance. As a Non-Executive Director and Company Secretary of a number of ASX listed companies he has over 25 years of boardroom experience and has developed a practical blend of legal and commercial acumen. He has served as a consultant to listed, public and private companies in the resources, property and biotech sectors focussing on stock exchange and regulatory compliance and a wide range of corporate transactions. Andrew has been the Company Secretary since 11 October 2013.
    Dr Robert Peach Non-Executive Director Sep 2015
    Dr Peach has over 30 years of drug discovery and development experience in the Pharmaceutical and Biotechnology industry. Dr Peach held senior executive and scientific positions in other companies including Apoptos, Biogen Idec, IDEC and Bristol-Myers Squibb, supporting in-licensing, acquisition and venture investments. His drug discovery and development experience in autoimmune and inflammatory diseases, and cancer has resulted in multiple drugs entering clinical trials and 3 registered drugs. He is also member of Risk Committee.
    Ms Jane Catherine Bell Non-Executive Director Apr 2021
    Ms Bell has more than 30 years of experience in leading law firms, financial services and corporate treasury operations gained living in Melbourne, London, Toronto, San Francisco and Brisbane. Ms Bell has been a non-executive director since 2002, serving on 17 boards including public and private hospitals, biotechnology, medical research and funds management boards. He is also Chair of Risk Committee.
    Dr Warwick Bonner Tong Non-Executive DirectorNon-Executive Chairman May 2018
    Dr Tong has more than 30 years of experience in the Pharmaceutical and Biotechnology industry. After his early career in General Medical Practice, Dr Tong has held a wide variety of roles in the pharmaceutical and biotech industry in NZ (Glaxo) Singapore (GlaxoWellcome) London (GSK), Boston (Surface Logix) and Melbourne (CTx Cancer Therapeutics CRC). His roles have included Medical Director, Regional Business Development Director (Asia Pacific), Commercial Strategy Director (International) and SVP Development (USA). Dr Tong is also a member of the Risk Committee.
    Dr Christopher John Burns Chief Executive OfficerManaging Director May 2018
    Dr Burns is a drug discovery leader having worked in various roles in pharma, biotech and academia for over 30 years. After 5 years he returned to Australia as a Research Fellow at the University of Sydney with the CRC for Molecular Engineering and Technology and after two years moved to the biotechnology company Ambri as Head of Chemistry. Chris then moved to the Melbourne-based biotech Cytopia as Head of Medicinal Chemistry and later as Research Director.
    Tim Luscombe Chief Financial Officer
    -
    Rhiannon Jones Chief Operating Officer
    -
    Jose Iglesias Clinical Adviser (Oncology)
    -
    Nicole Kruger Director Clinical Operations
    -
    Charlotte Mulder Director Early Clinical Development
    -
    Terrie-Anne Cock Director Translational Science
    -
    Paul Timpson FAK Biology Adviser
    -
    Margaret Frame FAK Biology Adviser
    -
    Adrian Sulistio Manager Product Development
    -
    Jason Lickliter Medical Adviser
    -
    Mark Devlin Scientific Adviser
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    HSBC Custody Nominees (Australia) Limited 52,609,304 19.37%
    BNP Paribas Noms Pty Ltd 21,612,234 7.96%
    Bond Street Custodians Limited (LAM1 D08047 A/C) 18,861,500 6.94%
    Citicorp Nominees Pty Limited 7,911,702 2.91%
    Ubs Nominees Pty Ltd 6,641,084 2.45%
    Elk River Holdings Pty Ltd 4,885,323 1.80%
    CTXT Pty Ltd 3,940,579 1.45%
    Dr Robert Peach 3,564,765 1.31%
    Christopher John Burns 3,134,470 1.15%
    HEH Enterprises Pty Ltd (HEH Enterprises Invest A/C) 3,102,500 1.14%
    M A Whiting and T A Whiting (Whiting Family S/F A/C) 3,083,510 1.14%
    Dr Warwick Tong 3,016,247 1.11%
    Mrs Jane Bell 2,835,664 1.04%
    Mr Anthony Hamilton Martin 2,820,323 1.04%
    J & J Stuart Pty Ltd (Stuart Family Super A/C) 2,700,000 0.99%
    Ravinna Pty Ltd (Ravinna A/C) 2,626,105 0.97%
    Mrs Sharon Lewis 2,430,000 0.89%
    GP Securities Pty Ltd 2,412,500 0.89%
    Mr Nicholas Dermott McDonald 2,216,673 0.82%
    34th Avenue Pty Ltd (Devlin Family A/C) 2,215,237 0.82%

    Profile

    since

    Note